Literature DB >> 2383736

Lymph node metastasis from melanoma with an unknown primary site.

A Jonk1, B B Kroon, P Rümke, W J Mooi, A A Hart, J A van Dongen.   

Abstract

Twenty-six patients, treated surgically between 1961 and 1986 because of lymph node metastasis from melanoma with an unknown primary, were analysed. Six patients had a history of spontaneous regression of a skin lesion. Following node dissection, the overall actuarial disease-free survival rate was 49 per cent, after both 5 and 10 years. When considered as single factors, female (versus male), one lymph node involved (versus more than one node involved) and site of metastasis in the groin or axilla (versus the neck) were found to have significantly favourable effects on prognosis with 5-year survival rates of 82 per cent (25 per cent), 82 per cent (27 per cent) and 80 per cent (11 per cent) respectively. However, at multifactorial analysis only the site of cervical metastases maintained a significant influence on survival (P = 0.005). As survival in this series is comparable with, or even better than, that of adequately treated patients with lymph node metastasis from a known primary melanoma, a radical node dissection is essential also in these patients.

Entities:  

Mesh:

Year:  1990        PMID: 2383736     DOI: 10.1002/bjs.1800770625

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  5 in total

1.  Melanoma with unknown primary: report and analysis of 24 patients.

Authors:  Rita Clerico; Ugo Bottoni; Giovanni Paolino; Marina Ambrifi; Paola Corsetti; Valeria Devirgiliis; Stefano Calvieri
Journal:  Med Oncol       Date:  2012-03-30       Impact factor: 3.064

2.  Microphthalmia transcription factor. A sensitive and specific melanocyte marker for MelanomaDiagnosis.

Authors:  R King; K N Weilbaecher; G McGill; E Cooley; M Mihm; D E Fisher
Journal:  Am J Pathol       Date:  1999-09       Impact factor: 4.307

3.  Molecular characterization and patient outcome of melanoma nodal metastases and an unknown primary site.

Authors:  Aleksandra Gos; Monika Jurkowska; Alexander van Akkooi; Caroline Robert; Hanna Kosela-Paterczyk; Senada Koljenović; Nyam Kamsukom; Wanda Michej; Arkadiusz Jeziorski; Piotr Pluta; Cornelis Verhoef; Janusz A Siedlecki; Alexander M M Eggermont; Piotr Rutkowski
Journal:  Ann Surg Oncol       Date:  2014-05-28       Impact factor: 5.344

4.  Melanoma of Unknown Primary: Evaluation of the Characteristics, Treatment Strategies, Prognostic Factors in a Monocentric Retrospective Study.

Authors:  Paolo Del Fiore; Marco Rastrelli; Luigi Dall'Olmo; Francesco Cavallin; Rocco Cappellesso; Antonella Vecchiato; Alessandra Buja; Romina Spina; Alessandro Parisi; Renzo Mazzarotto; Beatrice Ferrazzi; Andrea Grego; Alessio Rotondi; Clara Benna; Saveria Tropea; Francesco Russano; Angela Filoni; Franco Bassetto; Angelo Paolo Dei Tos; Mauro Alaibac; Carlo Riccardo Rossi; Jacopo Pigozzo; Vanna Chiarion Sileni; Simone Mocellin
Journal:  Front Oncol       Date:  2021-03-05       Impact factor: 6.244

5.  Treatment of Regional Metastatic Melanoma of Unknown Primary Origin.

Authors:  Elke J A H van Beek; Alfons J M Balm; Omgo E Nieweg; Olga Hamming-Vrieze; Peter J F M Lohuis; W Martin C Klop
Journal:  Cancers (Basel)       Date:  2015-08-10       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.